AC
CSBR icon

Aristides Capital’s Champions Oncology CSBR Stock Holding History

Aristides Capital’s Portfolio CSBR Stock Details CSBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11,822
Closed -$66.4K – 285
2023
Q4 		$66.4K Sell
11,822
-9,800
-45% -$54.7K 0.02% 254
2023
Q3 		$134K Hold
21,622
– – 0.06% 144
2023
Q2 		$138K Hold
21,622
– – 0.06% 156
2023
Q1 		$86.9K Hold
21,622
– – 0.05% 140
2022
Q4 		$97.5K Sell
21,622
-15,128
-41% -$98.8K 0.05% 219
2022
Q3 		$276K Hold
36,750
– – 0.21% 104
2022
Q2 		$294K Hold
36,750
– – 0.2% 104
2022
Q1 		$299K Hold
36,750
– – 0.18% 115
2021
Q4 		$307K Hold
36,750
– – 0.14% 134
2021
Q3 		$375K Hold
36,750
– – 0.14% 105
2021
Q2 		$378K Hold
36,750
– – 0.09% 104
2021
Q1 		$415K Sell
36,750
-3,250
-8% -$37.7K 0.17% 88
2020
Q4 		$432K Buy
+40,000
New +$413K 0.15% 81

Other funds holding CSBR

BMC
Battery Management Corp Boston, Massachusetts $426M AUM 21.5% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Aristides Capital's CSBR Position: Q1 2024 in Review

Aristides Capital sold out of Champions Oncology (CSBR) in Q1 2024, closing a stake of 11,822 shares — an estimated $66.4K sold.

Aristides Capital first reported a position in CSBR in Q4 2020 and held it in 13 quarters. The position peaked at $432K in Q4 2020. 25 funds tracked by Wall St. Rank hold CSBR as of Q1 2024.

  • Aristides Capital reported no remaining Champions Oncology position as of Q1 2024 after selling out during the quarter.
  • Aristides Capital sold 11,822 Champions Oncology shares in Q1 2024, an estimated $66.4K.
  • Aristides Capital first reported a position in Champions Oncology in Q4 2020 and held it in 13 quarters.
  • Aristides Capital's Champions Oncology position peaked at $432K in Q4 2020.
  • 25 funds tracked by Wall St. Rank held Champions Oncology as of Q1 2024.

Based on Aristides Capital's 13F filing for Q1 2024, filed 15 May 2024.